Tresiba (insulin degludec) is a protein pharmaceutical. Insulin degludec was first approved as Tresiba on 2013-01-20. It is used to treat hyperglycemia, type 1 diabetes mellitus, and type 2 diabetes mellitus in the USA. It has been approved in Europe to treat diabetes mellitus.
|Common Name||Insulin degludec|
|Indication||diabetes mellitus, hyperglycemia, type 1 diabetes mellitus, type 2 diabetes mellitus|